LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) had its price target dropped by equities researchers at Wells Fargo & Company from $104.00 to $94.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has an “equal weight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s price objective points to a potential upside of 9.97% from the company’s previous close.
LMAT has been the subject of several other reports. Citigroup reaffirmed a “market outperform” rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Wall Street Zen cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday. Citizens Jmp lifted their target price on LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th. Weiss Ratings cut LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, June 30th. Finally, Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Four investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $110.60.
Read Our Latest Analysis on LMAT
LeMaitre Vascular Stock Performance
LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). The firm had revenue of $70.38 million during the quarter, compared to the consensus estimate of $71.47 million. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. LeMaitre Vascular’s revenue was up 9.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.60 earnings per share. On average, equities analysts expect that LeMaitre Vascular will post 3 earnings per share for the current year.
Insiders Place Their Bets
In other news, Director Bridget A. Ross sold 5,044 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $111.10, for a total transaction of $560,388.40. Following the completion of the transaction, the director directly owned 3,942 shares in the company, valued at approximately $437,956.20. The trade was a 56.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO George W. Lemaitre sold 27,881 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $108.69, for a total value of $3,030,385.89. Following the transaction, the chief executive officer owned 1,430,019 shares of the company’s stock, valued at approximately $155,428,765.11. This represents a 1.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 54,453 shares of company stock worth $5,906,174. Insiders own 7.40% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada grew its stake in shares of LeMaitre Vascular by 1.5% in the first quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier’s stock worth $9,579,000 after purchasing an additional 1,735 shares in the last quarter. AQR Capital Management LLC lifted its holdings in LeMaitre Vascular by 36.4% in the first quarter. AQR Capital Management LLC now owns 27,878 shares of the medical instruments supplier’s stock worth $2,339,000 after purchasing an additional 7,445 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in LeMaitre Vascular by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier’s stock valued at $1,013,000 after buying an additional 539 shares in the last quarter. Millennium Management LLC increased its stake in LeMaitre Vascular by 119.8% during the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after buying an additional 115,141 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in LeMaitre Vascular by 27.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock valued at $22,019,000 after buying an additional 55,804 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.
Trending Headlines about LeMaitre Vascular
Here are the key news stories impacting LeMaitre Vascular this week:
- Positive Sentiment: LeMaitre reported second-quarter revenue of $70.38 million, up 9.6% year over year, while earnings increased to $0.74 per share from $0.60 a year earlier. The company also declared a quarterly dividend of $0.25 per share, payable September 3 to shareholders of record August 20, implying an annualized yield of approximately 0.9%. LeMaitre Q2 2026 Financial Results
- Neutral Sentiment: The company’s Q4 2026 EPS outlook of $0.75-$0.81 brackets the $0.79 analyst consensus, suggesting near-term results may be broadly in line with expectations. Q2 2026 Earnings Call Transcript
- Negative Sentiment: Second-quarter EPS of $0.74 missed the $0.81 consensus estimate, while revenue of $70.38 million was below expectations of $71.47 million. The earnings miss may weigh on the stock, despite year-over-year growth. LeMaitre Vascular Q2 Earnings and Revenues Lag Estimates
- Negative Sentiment: LeMaitre reduced its third-quarter EPS guidance to $0.66-$0.71 versus the $0.73 consensus and lowered full-year EPS guidance to $2.84-$2.94 versus $3.00 expected. Full-year revenue guidance of $274.3 million-$278.3 million also trails the $279.9 million consensus.
- Negative Sentiment: Barrington Research downgraded LMAT from “outperform” to “market perform,” signaling reduced conviction in further share-price outperformance. Finviz
About LeMaitre Vascular
LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.
Founded in 1983 by George D.
Read More
- Five stocks we like better than LeMaitre Vascular
- The FTC Is Suing Hims & Hers Health—Here’s Why Investors Shouldn’t Panic
- 3 Stocks Taking Very Different Routes Through the Summer Rally
- Is ADM’s Rally Getting Ahead of Its Policy Tailwind?
- CoreWeave Powers Up: The Asia Infrastructure Grab
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.
